Nuvectis Pharma, Inc. — Director's Dealing 2022

Oct 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-09-28

Reporting Person: BENTSUR RON (Director, Chairman & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-28	Common Stock	P	500	$7.23	Acquired	3012609	Direct
2022-09-30	Common Stock	P	500	$7.46	Acquired	3013109	Direct

Footnotes

F1: Includes 96,759 shares of restricted stock and 120,000 restricted stock units.